Good Returns | 05/06/2020 06:02 PM | Click to read full article
On Friday, shares of Sun Pharma gained as much as 3.3 percent after the company informed the stock exchanges that it has commenced Phase II clinical trial on AQCH, a phytopharmaceutical (plant-derived) drug for the treatment of COVID-19. The drugmaker had received approval from the DCGI for conducting Phase II clinical trial in April this year. The trial will be conducted across 12 centers in India in 210 patients. The treatment duration will be 10 days and results of the trial are expected by October 2020.